Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ Sustains Strong China Growth Via Commercial Innovation

Executive Summary

AstraZeneca’s strong showing in China in the third quarter was driven by a combination of expanded coverage, investment in patient access efforts and an innovative commercial model. New introductions Tagrisso and Farxiga are also expected to add to the momentum.

You may also be interested in...

Partnering In China – Slow Gains In Store?

As more multinational drug makers divest/license their maturing or non-core assets to local Chinese firms, a fast pick-up in sales in China via these alliances does not always appear to be ensured, at least early on. Scrip delves into one such recent agreement between Lilly and 3SBio, one of China's most successful biotechs.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts